News headlines about China Cord Blood (NYSE:CO) have trended somewhat positive on Friday, according to Accern. The research firm identifies negative and positive news coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. China Cord Blood earned a media sentiment score of 0.14 on Accern’s scale. Accern also gave media stories about the medical research company an impact score of 45.5146104451037 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

China Cord Blood (NYSE CO) opened at $10.02 on Friday. China Cord Blood has a 1-year low of $5.06 and a 1-year high of $14.95. The stock has a market capitalization of $1,212.07, a price-to-earnings ratio of 28.71 and a beta of 0.88.

WARNING: “Somewhat Favorable Press Coverage Somewhat Unlikely to Affect China Cord Blood (CO) Stock Price” was posted by Watch List News and is owned by of Watch List News. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this story can be accessed at https://www.watchlistnews.com/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-china-cord-blood-co-stock-price/1777611.html.

China Cord Blood Company Profile

China Cord Blood Corporation is a provider of cord blood banking services in China. The Company and its subsidiaries are principally engaged in the provision of umbilical cord blood storage and ancillary services in the People’s Republic of China. It provides cord blood testing, processing and storage services under the direction of subscribers for a cord blood processing fee and a storage fee.

Insider Buying and Selling by Quarter for China Cord Blood (NYSE:CO)

Receive News & Ratings for China Cord Blood Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Cord Blood and related companies with MarketBeat.com's FREE daily email newsletter.